Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
spartalizumab + LCL161
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The combination of **spartalizumab** (a humanized monoclonal antibody targeting PD-1) and **LCL161** (an orally bioavailable small molecule inhibitor of inhibitor of apoptosis proteins, or IAPs) is an investigational therapy studied for advanced and relapsed/refractory cancers such as multiple myeloma. Spartalizumab is an immune checkpoint inhibitor that blocks PD-1, thereby enhancing T cell-mediated anti-tumor responses. LCL161 acts as a SMAC mimetic, antagonizing IAPs, leading to the induction of apoptosis in tumor cells. This combination aims to synergistically enhance anti-tumor immunity and apoptosis in cancer cells. Both drugs are primarily developed by Novartis.
- Other names
- spartalizumab + LCL161PDR001 + LCL161
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IAP (Inhibitor of apoptosis protein family)cIAP1 BIR3 (Cellular inhibitor of apoptosis protein 1 (cIAP1) BIR3 domain)
Beyond the preview
Go deeper on spartalizumab + LCL161.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on spartalizumab + LCL161.